-
-
-
-
-
-
-
Mereo BioPharma (MREO) Issues Letter to Rubric Capital Management
-
-
-
-
-
-
-
Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
-
-
-
-
-
-
-
Business Update and Directorate Change
-
-
-
-
-
-
-
Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
-
-
-
-
-
-
-
Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 17, 2019
-
-
-
-
-
-
-
Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the
-
-
-
-
-
-
-
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary S
-
1,167,280 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

